Peptides and Sleep: What the Research Says

Sleep and wakefulness are regulated in part by neuropeptides — short signalling molecules made in the brain. When published research is grouped under the heading of "peptides and sleep," the overwhelming majority of it concerns a single system: orexin (also called hypocretin), a hypothalamic neuropeptide, and the receptors it acts on. This page surveys that literature compound by compound, notes what each study actually measured, in whom, and flags where the evidence came from animals or from uncontrolled records rather than randomised human trials.

This page is for educational purposes only and is not medical advice; consult a licensed physician about sleep symptoms, diagnosis, or any prescribed or investigational therapy. Nothing here describes a protocol, and no compound is ranked, recommended or compared as superior to another.

An important distinction: peptide systems versus peptide drugs

Orexin itself is a peptide. Most of the drugs studied in the sleep literature that act on it — lemborexant, daridorexant, suvorexant, danavorexton — are not peptides; they are small molecules that block or stimulate orexin receptors. Reviews of orexin deficiency in narcolepsy have described the molecular mechanisms, clinical phenotypes and emerging therapeutic directions built around this peptide system (PMID 41076550). Readers searching for "peptides for sleep" frequently land on this body of work because the target is peptidergic, even when the tested molecule is not. Keeping that distinction visible is the difference between reading the literature accurately and over-reading it.

Orexin biology: what reviews and tissue studies reported

The clearest human link between a peptide and a sleep disorder is narcolepsy. A 2023 review of the narcolepsies summarised the classification, diagnostic approach and therapeutic landscape as of that year (PMID 37634997). A separate 2025 review examined orexin deficiency in narcolepsy in more depth, covering proposed molecular mechanisms, clinical phenotypes and therapeutic frontiers under investigation (PMID 41076550). Both are narrative syntheses rather than primary data, which matters when weighing how much any single statement in them rests on controlled evidence.

Orexin loss has also been examined outside narcolepsy. Researchers reported reduced orexin immunoreactivity in Perry syndrome and in multiple system atrophy (PMID 28651750) — a tissue-level observation in neurodegenerative disease, not a treatment study and not a measurement of sleep quality in living participants.

A 2025 review addressed orexin-A and circadian disruption in Alzheimer's disease and discussed implications for amyloid-beta pathology (PMID 41335394). That paper sits at the mechanistic and hypothesis-generating end of the spectrum; it describes a proposed relationship rather than demonstrating that altering orexin changes disease course in people.

Orexin receptor agonists (wake-promoting direction)

Danavorexton (TAK-925)

Danavorexton is an orexin 2 receptor-selective agonist. A study published in the Journal of Sleep Research reported that danavorexton promoted wakefulness in non-human primates and in healthy individuals (PMID 36934366). The design spanned two very different populations — an animal model and healthy human volunteers — which is typical of early translational pharmacology and is not the same as demonstrating benefit in a diagnosed patient population over time.

Animal-only signals from OX2R agonism

Not every measured effect of orexin 2 receptor agonism concerns sleep. Researchers examined the effects of an orexin receptor 2-selective agonist on salivary secretion in rats (PMID 41844849). That work is animal-only, and its relevance to human physiology has not been established by the paper itself. It is included here because it illustrates a general point: receptor systems studied for sleep also sit upstream of unrelated autonomic functions.

Orexin receptor antagonists (sleep-promoting direction)

Dual orexin receptor antagonists (DORAs) block orexin signalling rather than mimic it. This is the most extensively trialled part of the orexin sleep literature in humans.

Lemborexant

The phase 3 randomised clinical trial SUNRISE 2 compared lemborexant with placebo in adults with insomnia disorder and reported on long-term efficacy and tolerability (PMID 32585700). A randomised, double-blind crossover clinical trial separately evaluated the efficacy and safety of lemborexant in people with liver cirrhosis (PMID 42414855) — a population relevant because hepatic metabolism influences drug handling.

Daridorexant

Daridorexant was described in Annals of Neurology as a new dual orexin receptor antagonist developed to treat insomnia disorder (PMID 31953863).

Suvorexant and lemborexant in routine records

A retrospective study assessed the short-term efficacy and safety of suvorexant and lemborexant (PMID 39512953). Retrospective chart-based work does not randomise, does not blind, and cannot separate drug effects from the reasons a clinician chose one agent over another — a limitation the design carries by definition.

Non-sleep outcomes measured during sleep

One human study took a metabolic angle: researchers reported that an orexin receptor antagonist increased fat oxidation and suppressed protein catabolism during sleep in humans (PMID 38993665). The outcomes there were metabolic substrate measures during the sleep period, not subjective sleep satisfaction.

Preclinical neurodegeneration work

In mice, dual orexin receptor antagonism with lemborexant enhanced microglial clearance of β-amyloid (PMID 42174655). This finding is animal-only. It does not establish that the same mechanism operates in people, and it says nothing about clinical outcomes in humans.

What each study measured, and in whom

Objective sleep metrics versus self-report

Sleep studies differ sharply in how they define an outcome. Broadly, three tiers appear across this literature:

• Objective physiological measures — polysomnography, actigraphy, or laboratory wakefulness testing. The danavorexton work reported wakefulness outcomes in non-human primates and healthy individuals (PMID 36934366), and the metabolic study measured substrate oxidation during the sleep period in humans (PMID 38993665).
• Patient-reported outcomes — sleep diaries and questionnaires, common endpoints in insomnia trials such as the placebo-controlled phase 3 programme for lemborexant (PMID 32585700).
• Clinician-recorded impressions — as captured in retrospective work on suvorexant and lemborexant (PMID 39512953).

An improvement measured one way does not automatically appear the other way. A compound can shift an objective metric without changing how a night feels, and the reverse also occurs.

Adverse Events and Tolerability: What Studies Report

Safety information in this citation set came mainly from the human trials rather than from mechanistic work. The SUNRISE 2 phase 3 randomised clinical trial examined long-term tolerability of lemborexant alongside efficacy in adults with insomnia disorder (PMID 32585700). A randomised, double-blind crossover trial specifically evaluated safety as well as efficacy of lemborexant in liver cirrhosis (PMID 42414855), and a retrospective study reported on short-term safety of suvorexant and lemborexant in treated patients (PMID 39512953). Animal findings such as the salivary secretion effects of an orexin receptor 2-selective agonist in rats (PMID 41844849) describe physiological responses in rodents and have not been shown to correspond to human tolerability. Specific event rates are not reproduced here; the primary papers are the appropriate source for those figures.

Where the evidence is thin, indirect, or animal-only

Several limitations run through this literature and are worth stating plainly:

1. Animal-only findings stay animal-only until replicated in people. The amyloid-clearance result with lemborexant was obtained in mice (PMID 42174655), as were the salivary secretion observations (PMID 41844849).
2. Mechanism is not outcome. Reviews linking orexin-A to circadian disruption in Alzheimer's disease propose implications for amyloid-beta pathology (PMID 41335394) rather than demonstrating clinical change.
3. Healthy volunteers are not patients. Wake-promoting effects reported for danavorexton involved non-human primates and healthy individuals (PMID 36934366); reviews of narcolepsy describe a different clinical context altogether (PMID 37634997).
4. Many circulating "sleep peptide" names have no trial data in this citation set. Where a compound is discussed publicly but no verified published sleep trial is cited on this page, that absence is the honest summary — not an implied endorsement and not an implied dismissal.

Regulatory context

Orexin receptor antagonists including lemborexant and daridorexant are prescription pharmaceuticals evaluated in regulated clinical trial programmes for insomnia disorder (PMID 32585700, PMID 31953863). Investigational agents such as danavorexton were studied under research protocols (PMID 36934366). Research-use-only materials, by contrast, are not approved for human administration in any indication, and their labelling reflects laboratory use. Regulatory status varies by country and changes over time.

Reading the literature carefully

Four questions separate a strong claim from a weak one in this field: who was studied, how sleep was measured, whether there was a control group, and how long the observation lasted. A phase 3 randomised placebo-controlled trial in adults with insomnia disorder (PMID 32585700) answers those questions differently from a retrospective record review (PMID 39512953) or a mouse experiment (PMID 42174655). Applying the same four questions to every headline is the most durable skill a reader of peptide literature can develop.

References

• Narcolepsies, update in 2023 (Revue neurologique, 2023)
• Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individuals (Journal of Sleep Research, 2023)
• Dual orexin receptor antagonism with lemborexant enhances microglial clearance of β-amyloid in mice (Molecular Neurodegeneration, 2026)
• Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2 (Sleep, 2020)
• Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder (Annals of Neurology, 2020)
• Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis-Randomized, Double-Blind, Crossover Clinical Trial (Alimentary Pharmacology & Therapeutics, 2026)
• Orexin receptor antagonist increases fat oxidation and suppresses protein catabolism during sleep in humans (iScience, 2024)
• Short-Term Efficacy and Safety of Suvorexant and Lemborexant: A Retrospective Study (Cureus, 2024)
• Effects of an orexin receptor 2-selective agonist on salivary secretion in rats (Scientific Reports, 2026)
• Reduced orexin immunoreactivity in Perry syndrome and multiple system atrophy (Parkinsonism & Related Disorders, 2017)
• Orexin Deficiency in Narcolepsy: Molecular Mechanisms, Clinical Phenotypes, and Emerging Therapeutic Frontiers (Brain and Behavior, 2025)
• Orexin-A and Circadian Disruption in Alzheimer's Disease: Implications for Amyloid-Beta Pathology (Molecular Neurobiology, 2025)